Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer

We examined whether mTOR inhibition by RAD001 (Everolimus) could be therapeutically efficacious in the treatment of bladder cancer. RAD001 markedly inhibited proliferation of nine human urothelial carcinoma cell lines in dose- and sensitivity-dependent manners in vitro.  FACS analysis showed that tr...

Full description

Saved in:
Bibliographic Details
Published in:Cancer biology & therapy 2009-12, Vol.8 (24), p.2339-2347
Main Authors: Mansure, Jose J., Nassim, Roland, Chevalier, Simone, Rocha, Joice, Scarlata, Eleonora, Kassouf, Wassim
Format: Article
Language:English
Subjects:
Animals
Apoptosis
Binding
Biology
Bioscience
Calcium
Cancer
Carcinoma - drug therapy
Cell
Cell Cycle - drug effects
Cell Separation
Cycle
Dose-Response Relationship, Drug
Everolimus
Female
Flow Cytometry
Humans
Intracellular Signaling Peptides and Proteins - antagonists & inhibitors
Intracellular Signaling Peptides and Proteins - metabolism
Landes
Mice
Neoplasm Transplantation
Neovascularization, Pathologic
Organogenesis
Protein-Serine-Threonine Kinases - antagonists & inhibitors
Protein-Serine-Threonine Kinases - metabolism
Proteins
Signal Transduction
Sirolimus - analogs & derivatives
Sirolimus - pharmacology
TOR Serine-Threonine Kinases
Urinary Bladder Neoplasms - drug therapy
Urothelium - pathology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!